Results 1 to 10 of about 6,142,918 (314)

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer

Journal of Clinical Oncology
PURPOSE Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with overall survival (OS) as the primary end point will take approximately a decade to complete.
Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A. Carducci, Matthew R. Smith, Michael J. Morris, Gwenaelle Gravis, David P. Dearnaley, Paul Verhagen, Takayuki Goto, Nick James, Marc E. Buyse, Jayne F. Tierney, Christopher Sweeney   +19 more
openaire   +3 more sources

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial

Current Oncology
Background: A single measurement or a summary of a limited number of measurements of CA125 was considered in the prediction of clinical outcomes for patients with ovarian cancer.
Chang Yin, Josee-Lyne Ethier, Mark S. Carey, Dongsheng Tu, Xueying Zheng   +4 more
doaj   +1 more source

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer

Journal of Cancer Research and Clinical Oncology, 2014
Purpose New treatment strategies, particularly the introduction of molecular-targeted agents and appropriate patient selection based on histology and/or genotyping, have progressed markedly in recent years, and the overall survival (OS) in advanced non ...
Masayuki Aboshi, Masayuki Kaneko, Mamoru Narukawa   +2 more
doaj   +1 more source

Cisplatin-based chemotherapy with or without bevacizumab for Chinese postmenopausal women with advanced cervical cancer: a retrospective observational study

BMC Cancer, 2020
Background The purpose of this study was to assess the efficacy and safety of cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women with advanced cervical cancer (ACC).
Xiaoli He, Jun Liu, Li Xiao, Mingdong Zhao, Tingting Su, Tiejian Liu, Guowei Han, Yue Wang   +7 more
doaj   +1 more source

Combination of pemetrexed with bevacizumab for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Combining pemetrexed with bevacizumab may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of pemetrexed addition to bevacizumab on treatment ...
Wei Fang, Xingqiao Peng, Qun Zhou
doaj   +1 more source

Long-term outcomes and prognostic factors after surgery alone for brain arteriovenous malformation

Brain Circulation
OBJECTIVES: There is a paucity of data regarding the long-term hemorrhage/progression outcomes of brain arteriovenous malformation (BAVM). The purpose of this study was to examine the outcomes of surgical treatment alone over a long follow-up period ...
Zhao-Ying Zhu, Wei Zhang, Li-Chuan Gao, Gui-Jun Zhang, Jing Chen   +4 more
doaj   +1 more source

Peritumoral infiltration of CD3 lymphocytes makes a difference in prostate cancer [PDF]

Vojnosanitetski Pregled
Background/Aim. Prostate cancer (PC) is the second most common malignancy in men, and the fifth leading cause of cancer death. The most important prognostic parameters are tumor, node, and metastasis (TNM) status, initial prostate-specific antigen (PSA),
Vještica Milka, Trivunić-Dajko Sandra, Babić Božana, Jungić Saša, Berendika Jelena   +4 more
doaj   +1 more source

Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer

OncoTargets and Therapy, 2014
Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC).
Beauchemin,Catherine, Cooper,Dan, Lapierre,Marie-Ève, Yelle,Louise, Lachaine,Jean   +4 more
openaire   +4 more sources

Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis

Frontiers in Oncology
BackgroundCirculating tumor DNA (ctDNA) is an emerging biomarker in cervical cancer, with elevated levels typically indicating a higher tumor burden. However, its prognostic value in cervical cancer patients remains debated.
Xiumin Zhao, Shufu Hou, Ruiqi Hao, Yelei Zang, Dandan Song   +4 more
doaj   +1 more source

Pre-Existing Diabetes Limits Survival Rate After Immune Checkpoint Inhibitor Treatment for Advanced Lung Cancer: A Retrospective Study in Japan

Diabetes, Metabolic Syndrome and Obesity, 2021
Kaori Hisanaga,1 Hiroshi Uchino,1 Naoko Kakisu,1 Masahiko Miyagi,1 Fukumi Yoshikawa,1 Genki Sato,1 Kazutoshi Isobe,2 Kazuma Kishi,2 Sakae Homma,3 Takahisa Hirose1 1Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho ...
Hisanaga K, Uchino H, Kakisu N, Miyagi M, Yoshikawa F, Sato G, Isobe K, Kishi K, Homma S, Hirose T   +9 more
doaj